PKM2 inhibitor (compound 3k): Selective Disruption of Cancer Cell Glycolysis

Executive Summary: PKM2 inhibitor (compound 3k), also known as SKU B8217 from APExBIO, selectively inhibits pyruvate kinase M2 (PKM2), a central glycolytic enzyme overexpressed in many tumors (product page). It shows an IC₅₀ of 2.95 μM against PKM2 and nanomolar-level antiproliferative activity in several cancer cell lines, including HCT116 and Hela, with minimal cytotoxicity toward normal cells. In vivo, oral dosing at 5 mg/kg every two days for 31 days significantly inhibits ovarian tumor xenograft growth in BALB/c nude mice without major toxicity. Mechanistic studies confirm that the compound disrupts cancer cell glycolysis and modulates immune cell polarization, as validated in peer-reviewed studies (Wu et al., 2025). These properties make compound 3k a promising research tool and candidate for targeted cancer metabolism therapies.

Biological Rationale

Pyruvate kinase M2 (PKM2) is a key rate-limiting enzyme in the glycolytic pathway. It is predominantly expressed in tumor cells and drives aerobic glycolysis, a metabolic hallmark of cancer known as the Warburg effect (Wu et al., 2025). Cancer cells rely on high glycolytic flux to support rapid proliferation and survival, even in the presence of oxygen. Inhibiting PKM2 disrupts this process, selectively impairing cancer cell metabolism while sparing normal cells that express other PK isoforms. This specificity underpins the therapeutic rationale for targeting PKM2 in oncology (see related analysis: this article extends the discussion by focusing on validated quantitative benchmarks in vitro and in vivo).

Mechanism of Action of PKM2 inhibitor (compound 3k)

PKM2 inhibitor (compound 3k) is a potent, selective inhibitor that binds to the active site of PKM2, blocking its catalytic function (APExBIO). The compound displays an IC₅₀ of 2.95 μM for PKM2 in cell-free enzymatic assays. By inhibiting PKM2, compound 3k disrupts the conversion of phosphoenolpyruvate to pyruvate, leading to reduced ATP production via glycolysis and accumulation of upstream glycolytic intermediates. This metabolic blockade induces energy stress in PKM2-overexpressing cancer cells, triggering autophagic cell death and suppressing proliferation (Wu et al., 2025).

Evidence & Benchmarks

• Compound 3k inhibits PKM2 enzymatic activity with an IC₅₀ of 2.95 μM in biochemical assays (APExBIO, product page).
• Demonstrates antiproliferative activity against HCT116 (IC₅₀: 0.18 μM), Hela (IC₅₀: 0.29 μM), and H1299 (IC₅₀: 1.56 μM) cell lines, all characterized by high PKM2 expression (APExBIO).
• Shows reduced cytotoxicity toward normal BEAS-2B cells, indicating selectivity for PKM2-overexpressing cancer cells (APExBIO).
• In vivo, oral administration at 5 mg/kg every two days for 31 days significantly reduces tumor volume and weight in SK-OV-3 ovarian cancer xenografted BALB/c nude mice, with no significant organ toxicity or weight loss (APExBIO).
• In severe acute pancreatitis (SAP) mouse models, PKM2 inhibitor administration reverses USP7-knockdown protection, validating PKM2’s role in metabolic reprogramming and immune cell polarization (Wu et al., 2025).

Applications, Limits & Misconceptions

Compound 3k is used as a research tool to dissect cancer metabolism, immunometabolic signaling, and autophagic cell death induction. It is also under investigation as a candidate for targeted cancer therapies, especially in tumors with elevated PKM2. Recent mechanistic studies have highlighted its utility in modulating immune cell phenotypes, particularly macrophage polarization, by interrupting PKM2-mediated signaling (Wu et al., 2025).

This article updates the practical workflow guidance described in Solving Lab Assay Challenges with PKM2 Inhibitor (Compound 3k) by providing peer-reviewed outcome metrics and a comparative analysis of selectivity in cancer versus normal cells.

Common Pitfalls or Misconceptions

• PKM2 inhibitor (compound 3k) is not effective in tumors with low or absent PKM2 expression.
• It does not target other pyruvate kinase isoforms (e.g., PKM1, PKL, PKR) and has minimal off-target glycolytic disruption.
• Long-term solution storage (>1 week) is not recommended due to compound instability; freshly prepare working solutions.
• Ineffective when dissolved in ethanol or water due to poor solubility—use DMSO with gentle warming for ≥34.5 mg/mL stocks.
• Not indicated for clinical therapeutic use; all current data are preclinical (APExBIO).

Workflow Integration & Parameters

Compound 3k is provided as a solid (molecular weight: 345.48; formula: C₁₈H₁₉NO₂S₂). For laboratory use, dissolve in DMSO (≥34.5 mg/mL) with gentle warming. The compound is insoluble in ethanol and water. Store at -20°C; avoid repeated freeze-thaw cycles. Working solutions should be prepared fresh and not stored long term. For cell-based assays, titrate concentrations based on cell line PKM2 expression. In vivo mouse studies have used oral dosing of 5 mg/kg every two days for 31 days without major adverse effects (APExBIO).

To maximize reproducibility and interpretability in metabolic and viability assays, see the extended workflow recommendations in Resolving Laboratory Challenges with PKM2 inhibitor (compound 3k); this article supplements those protocols with recent in vivo efficacy benchmarks and updated selectivity data.

Conclusion & Outlook

PKM2 inhibitor (compound 3k), supplied by APExBIO, is a potent, selective tool for investigating PKM2-driven cancer metabolism and immune cell reprogramming. Its nanomolar efficacy in vitro and significant tumor suppression in vivo, alongside validated selectivity for PKM2-overexpressing cells, underscore its translational research value. Ongoing studies are clarifying its broader impact on immunometabolic signaling and autophagic cell death. For advanced mechanistic context and future translational directions, see PKM2 Inhibition as a Cornerstone Strategy: Mechanistic Insights, which this article extends by providing product-specific, quantitative evidence and direct workflow guidance.